Eculizumab · Soliris

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: Paroxysmal Nocturnal Hemoglobinuria, Generalized Myasthenia Gravis, Myasthenia Gravis, Thrombotic Microangiopathy

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (5)
US
  • Treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positiveFDA label
  • Atypical Hemolytic Uremic Syndrome (aHUS) SOLIRIS is indicated for the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. Limitation of Use SOLIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).
    FDA label
Product first approved 2007Outside this platform's coverage
JP
  • Reduce hemolysis in patients with paroxysmal nocturnal hemoglobinuria
Product first approved 2010PMDA
CA
  • SOLIRIS (eculizumab for injection) is indicated for: • Paroxysmal Nocturnal Hemoglobinuria (PNH) Soliris (eculizumab for injection) is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. SOLIRIS was studied in clinical trials in patients with a history of at least one transfusion during the past two years (see 14 CLINICAL TRIALS). • Atypical Hemolytic Uremic Syndrome (atypical HUS) Soliris (eculizumab for injection) is indicated for the treatment of patients with atypical hemolytic uremic syndrome (atypical HUS) to reduce...
Product first approved 2009Health Canada
EU
  • Soliris is indicated in adults and children for the treatment of: Paroxysmal nocturnal haemoglobinuria (PNH). Evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history (see section 5.1). Atypical haemolytic uremic syndrome (aHUS). Soliris is indicated in adults for the treatment of: Refractory generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor (AChR) antibody-positive (see section 5.1). Neuromyelitis optica spectrum disorder (NMOSD) in patients who...
Product first approved 2007EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (32)
Generalized Myasthenia Gravis
NCT06764160 · Alexion Pharmaceuticals, Inc.
2025-01-06 – 2025-12-29 · Generalized Myasthenia Gravis (gMG), Refractory gMG
What this study did
NCT03759366 · Alexion Pharmaceuticals, Inc.
2018-12-28 – 2023-11-06 · Myasthenia Gravis, Myasthenia Gravis, Juvenile Form, Myasthenia Gravis, Generalized
What this study did
NCT02301624 · Alexion Pharmaceuticals, Inc.
2014-11-12 – 2019-01-15 · Refractory Generalized Myasthenia Gravis
What this study did
Paroxysmal Nocturnal Hemoglobinuria
NCT06449001 · Alexion Pharmaceuticals, Inc.
2025-08-11 – 2028-03-10 · Paroxysmal Nocturnal Hemoglobinuria, PNH, Extravascular Hemolysis
What this study did
NCT06593938 · Chengdu Suncadia Medicine Co., Ltd.
2024-10-25 – 2025-07-31 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
NCT05886244 · Alexion Pharmaceuticals, Inc.
2023-07-05 – 2025-04-14 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
NCT05131204 · Regeneron Pharmaceuticals
2022-10-06 – 2023-07-12 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
NCT06987864 · Biocad
2020-04-13 – 2022-11-02 · Paroxysmal Nocturnal Hemoglobinuria (PNH)
What this study did
NCT03818607 · Amgen
2019-01-22 – 2022-07-12 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
NCT04058158 · Samsung Bioepis Co., Ltd.
2019-08-07 – 2021-10-21 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
NCT03500549 · Apellis Pharmaceuticals, Inc.
2018-06-14 – 2020-08-13 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
NCT04679103 · AO GENERIUM
2018-05-03 – 2020-04-20 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
NCT00130000 · National Heart, Lung, and Blood Institute (NHLBI)
2005-08-09 – 2007-06-25 · Paroxysmal Hemoglobinuria, Nocturnal
What this study did
NCT00098280 · National Heart, Lung, and Blood Institute (NHLBI)
2004-12 – 2006-02 · Hemoglobinuria, Paroxysmal
What this study did
NCT00112983 · Jonsson Comprehensive Cancer Center
2004-11 – 2005-06 · Leukemia
What this study did
Other / comorbidity
NCT05726916 · Assistance Publique - Hôpitaux de Paris
2023-11-09 – 2027-11-09 · Hypertensive Emergency-associated Hemolytic Uremic Syndrome
What this study did
NCT07420296 · Tianjin Medical University General Hospital
2026-01-01 – 2027-06-30 · Neuromyelitis Optica Spectrum Disorders (NMOSD)
What this study did
NCT06724809 · Alexion Pharmaceuticals, Inc.
2025-01-16 – 2026-12-07 · NMOSD, Neuromyelitis Optica Spectrum Disorders
What this study did
NCT05702996 · University Hospital, Rouen
2023-03 – 2025-09 · Thrombotic Microangiopathies
What this study did
NCT04935177 · Hansa Biopharma AB
2021-10-14 – 2025-06-20 · Kidney Transplantation in Highly Sensitized Patients
What this study did
NCT05876351 · Alexion Pharmaceuticals, Inc.
2023-07-14 – 2025-05-07 · Atypical Hemolytic Uremic
What this study did
NCT04859608 · University Hospital, Tours
2021-10-20 – 2023-12-28 · Hemolytic-Uremic Syndrome, Atypical
What this study did
NCT04752566 · Alexion Pharmaceuticals, Inc.
2021-03-08 – 2022-08-03 · Guillain-Barre Syndrome
What this study did
NCT02003144 · Alexion Pharmaceuticals, Inc.
2015-01-12 – 2021-07-12 · Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
What this study did
NCT02013037 · Cedars-Sinai Medical Center
2012-11 – 2020-04-30 · Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant, Left Ventricular Dysfunction, Cardiac Allograft Vasculopathy, Heart Graft Dysfunction
What this study did
NCT01892345 · Alexion Pharmaceuticals, Inc.
2014-04-11 – 2018-07-17 · Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
What this study did
NCT02205541 · University Hospital, Toulouse
2015-06 – 2018-06 · Hemolytic Uremic Syndrome of Childhood
What this study did
Phase 2/3 (3)
Other / comorbidity
NCT04155424 · Alexion Pharmaceuticals, Inc.
2020-01-14 – 2023-07-31 · Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
What this study did
NCT02145182 · Alexion Pharmaceuticals, Inc.
2014-08-21 – 2016-11-22 · Delayed Graft Function
What this study did
NCT01410916 · Alexion Pharmaceuticals, Inc.
2011-07 – 2012-06 · Shiga-like Toxin-producing Escherichia Coli
What this study did
Phase 2 (39)
Generalized Myasthenia Gravis
NCT00727194 · Alexion Pharmaceuticals, Inc.
2008-10 – 2011-07 · Myasthenia Gravis
What this study did
Paroxysmal Nocturnal Hemoglobinuria
NCT05646563 · NovelMed Therapeutics
2027-01 – 2030-08 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
NCT05731050 · NovelMed Therapeutics
2026-06 – 2028-03 · PNH - Paroxysmal Nocturnal Hemoglobinuria
What this study did
NCT04702568 · BioCryst Pharmaceuticals
2020-12-18 – 2023-10-04 · Paroxysmal Nocturnal Hemoglobinuria, PNH
What this study did
NCT03472885 · Alexion Pharmaceuticals, Inc.
2018-05-08 – 2023-01-05 · Paroxysmal Nocturnal Hemoglobinuria (PNH)
What this study did
NCT03427060 · AKARI Therapeutics
2018-05-14 – 2021-02-03 · Paroxysmal Nocturnal Hemoglobinuria (PNH)
What this study did
NCT03030183 · Ra Pharmaceuticals
2017-04-17 – 2018-03-28 · Paroxysmal Nocturnal Hemoglobinuria (PNH)
What this study did
NCT01194804 · Alexion Pharmaceuticals, Inc.
2008-04 – 2011-03 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
NCT01192399 · Alexion Pharmaceuticals, Inc.
2007-11 – 2008-06 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
Thrombotic Microangiopathy
NCT07707687 · First Affiliated Hospital of Zhejiang University
2026-07-10 – 2028-07-10 · Transplant-Associated Thrombotic Microangiopathy (TA-TMA)
What this study did
NCT03518203 · Children's Hospital Medical Center, Cincinnati
2018-08-03 – 2022-06-01 · Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome, Multiple Organ Dysfunction Syndrome
What this study did
Other / comorbidity
NCT06673394 · Tianjin Medical University General Hospital
2025-09-03 – 2026-12-01 · Neuromyelitis Optica Spectrum Disorder Attack
What this study did
NCT07184840 · Tianjin Medical University General Hospital
2025-09-09 – 2026-09-30 · Neuromyelitis Optica Spectrum Disorder Attack
What this study did
NCT06513338 · Peking University First Hospital
2024-03-01 – 2025-11-03 · Autoimmune Diseases
What this study did
NCT04725812 · Cedars-Sinai Medical Center
2021-09-13 – 2021-12-07 · Preeclampsia, Severe Preeclampsia, Eculizumab, HELLP, HELLP Syndrome, HELLP Syndrome Second Trimester, Pregnancy Related, AHUS, PNH, Complement Regulatory Factor Defect, Complement Abnormality, HELLP Syndrome Third Trimester
What this study did
NCT04346797 · Assistance Publique - Hôpitaux de Paris
2020-04-16 – 2020-12-31 · SARS-CoV-2, COVID19
What this study did
NCT02727608 · Uppsala University
2016-05-15 – 2018-06 · Diabetes Mellitus
What this study did
NCT01756508 · Russian Academy of Medical Sciences
2012-09-01 – 2017-12-01 · End-Stage Renal Disease, Kidney Failure, Graft Reperfusion Injury
What this study did
NCT01919346 · Heeger, Peter, M.D.
2013-08 – 2017-12 · Delayed Graft Function, Kidney Transplantation, Complement Activity
What this study did
NCT02093533 · Mario Negri Institute for Pharmacological Research
2014-03 – 2017-12 · Membranoproliferative Glomerulonephritis
What this study did
NCT02298933 · National Heart, Lung, and Blood Institute (NHLBI)
2014-11-21 – 2017-08-08 · Thrombocytopenia, Alloimmune Platelet Refractoriness
What this study did
NCT02493725 · Chiba University
2015-07 – 2016-10 · Gullain Barre Syndrome
What this study did
NCT01895127 · Brigham and Women's Hospital
2013-11 – 2016-04 · Antibody-mediated Rejection, Humoral Rejection
What this study did
NCT02029378 · NHS Greater Glasgow and Clyde
2014-09 – 2016-03 · Gullian Barre Syndrome
What this study did
NCT01399593 · Alexion Pharmaceuticals, Inc.
2011-11-02 – 2015-11-13 · Antibody Mediated Rejection
What this study did
NCT01303952 · University Hospital, Essen
2011-01 – 2015-06 · Cold Agglutinin Disease
What this study did
NCT01193348 · Alexion Pharmaceuticals, Inc.
2010-09 – 2014-04 · Atypical Hemolytic-Uremic Syndrome
What this study did
NCT01403389 · Schroppel, Bernd, M.D.
2011-12-01 – 2014-02-06 · Delayed Function of Renal Transplant
What this study did
NCT01194973 · Alexion Pharmaceuticals, Inc.
2010-07 – 2014-02 · Atypical Hemolytic-Uremic Syndrome
What this study did
NCT00844428 · Alexion Pharmaceuticals, Inc.
2009-07 – 2013-12 · Atypical Hemolytic Uremic Syndrome
What this study did
NCT01757431 · Alexion Pharmaceuticals, Inc.
2012-05-16 – 2013-09-25 · Atypical Hemolytic Uremic Syndrome (aHUS)
What this study did
NCT00935883 · Philip J. Rosenfeld, MD, PhD
2009-07 – 2013-08 · Age-Related Macular Degeneration
What this study did
NCT00844844 · Alexion Pharmaceuticals, Inc.
2009-05 – 2013-07 · Atypical Hemolytic Uremic Syndrome
What this study did
NCT01275287 · University of North Carolina, Chapel Hill
2011-05 – 2012-12 · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
What this study did
NCT01029587 · Johns Hopkins University
2009-11 – 2010-05-06 · Antiphospholipid Antibody Syndrome, End Stage Renal Disease
What this study did
NCT00485576 · Alexion Pharmaceuticals, Inc.
2007-09 – 2008-11 · Allergic Asthma
What this study did
Phase 1/2 (7)
Other / comorbidity
NCT06453135 · Tao Lin
2024-07 – 2025-12 · Kidney Transplantation
What this study did
NCT02113891 · Assistance Publique - Hôpitaux de Paris
2015-02 – 2017-11 · Subclinical Acute Antibody-mediated Rejection in Kidney Transplantation
What this study did
NCT00670774 · Mark Stegall
2008-03 – 2017-08 · Kidney Transplant
What this study did
NCT01106027 · Mayo Clinic
2010-03 – 2016-08-19 · Kidney Transplant
What this study did
NCT01095887 · Mayo Clinic
2010-05 – 2014-04 · Kidney Transplant
What this study did
NCT01579838 · Hadassah Medical Organization
2012-02 – 2013-03 · Chronic Hemolysis
What this study did
NCT00904826 · Mayo Clinic
2009-04 – 2011-12 · Neuromyelitis Optica, Devic's Disease
What this study did
Phase 1 (5)
Other / comorbidity
NCT03468140 · Yale University
2021-10-01 – 2023-12-31 · End Stage Liver Disease
What this study did
NCT04103489 · Johns Hopkins University
2021-02-23 – 2023-09-04 · HELLP Syndrome (HELLP), Third Trimester, Complement Abnormality, Morbidity;Newborn, Maternal Injury, Preeclampsia Severe
What this study did
NCT03722329 · Samsung Bioepis Co., Ltd.
2018-11-13 – 2019-04-08 · Healthy
What this study did
NCT01327573 · Sanjay Kulkarni
2011-03 – 2015-02 · Kidney; Complications, Allograft
What this study did
NCT01221181 · Columbia University
2010-07 – 2011-10 · Dense Deposit Disease, Membranoproliferative Glomerulonephritis
What this study did
Phase 4 (5)
Paroxysmal Nocturnal Hemoglobinuria
NCT04320602 · Alexion Pharmaceuticals, Inc.
2021-04-14 – 2022-12-20 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
NCT00867932 · Alexion Pharmaceuticals, Inc.
2009-10-02 – 2011-05-12 · Hemoglobinuria, Paroxysmal
What this study did
Other / comorbidity
NCT07010302 · Massachusetts General Hospital
2026-09-01 – 2030-05 · NMOSD
What this study did
NCT07410039 · Chinese PLA General Hospital
2026-02-01 – 2029-06-30 · Neuromyelitis Optica Spectrum Disorder Attack
What this study did
NCT02574403 · Nantes University Hospital
2015-11 – 2019-12-03 · Atypical Hemolytic Uremic Syndrome
What this study did
Used as active comparator (15)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (12)
Paroxysmal Nocturnal Hemoglobinuria
NCT07816237 · Bisirna Therapeutics (Suzhou) Co., Ltd.
2026-10-29 – 2029-12-31 · Paroxysmal Nocturnal Hemoglobinuria, PNH
What this study did
NCT07747090 · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
2026-12-10 – 2028-07-31 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
NCT04432584 · Hoffmann-La Roche
2020-09-30 – 2027-04-18 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
NCT04434092 · Hoffmann-La Roche
2020-10-08 – 2027-04-18 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
NCT07177859 · Nanjing Chia-tai Tianqing Pharmaceutical
2025-11 – 2026-11 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
NCT06932744 · Wuhan Createrna Science and Technology Co., Ltd
2024-08-30 – 2025-12-30 · Paroxysmal Nocturnal Haemoglobinuria (PNH)
What this study did
NCT06799546 · Haisco Pharmaceutical Group Co., Ltd.
2025-02-13 – 2025-11-05 · PNH
What this study did
NCT04558918 · Novartis Pharmaceuticals
2021-01-25 – 2023-03-06 · Paroxysmal Nocturnal Hemoglobinuria (PNH)
What this study did
NCT02946463 · Alexion Pharmaceuticals, Inc.
2016-12-12 – 2023-02-28 · Paroxysmal Nocturnal Hemoglobinuria (PNH)
What this study did
NCT03056040 · Alexion Pharmaceuticals, Inc.
2017-05-17 – 2022-02-21 · Paroxysmal Nocturnal Hemoglobinuria (PNH)
What this study did
NCT04060264 · Biocad
2019-04-04 – 2020-12-30 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
NCT04463056 · AO GENERIUM
2017-11-29 – 2018-10-16 · Paroxysmal Nocturnal Hemoglobinuria, Marchiafava-Micheli Syndrome, Paroxysmal Hemoglobinuria
What this study did
Phase 2 (1)
Paroxysmal Nocturnal Hemoglobinuria
NCT05116774 · BioCryst Pharmaceuticals
2021-12-06 – 2023-09-14 · Paroxysmal Nocturnal Hemoglobinuria (PNH)
What this study did
Phase 1 (2)
Other / comorbidity
NCT05863442 · Turgut Ardika PTY LTD
2023-04-10 – 2024-10-05 · Healthy
What this study did
NCT04027803 · Biocad
2018-09-21 – 2019-04-07 · Healthy Subjects
What this study did

Competitive landscape

6 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Myasthenia Gravis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Eculizumab (Soliris): this drugApprovedMonoclonal antibodyComplement C5Partial signal
NCT01997229: Myasthenia Gravis Activities of Daily Living Profile (MG-ADL): Change From Baseline in MG-ADL Total Score at Week 26 by Worst-Rank Analysis of Covariance (ANCOVA) (End of study (Week 26)): Eculizumab 56.6 scores on a scale (Standard Error 4.53) | Placebo 68.3 scores on a scale (Standard Error 4.49) missed
Avacincaptad Pegol (Izervay)
Approved(overall)
RNA AptamerComplement C5
Reliable signal(overall)
No reviewed efficacy summary in this indication
Efgartigimod Alfa (Vyvgart)ApprovedAntibody fragmentFcRnnot yet gradedNo reviewed efficacy summary in this indication
Ravulizumab (Ultomiris)ApprovedMonoclonal antibodyComplement C5not yet gradedNo reviewed efficacy summary in this indication
CemdisiranPhase 3RNA / oligonucleotideComplement C5not yet gradedNo reviewed efficacy summary in this indication
Descartes-08Phase 3Cell therapyBCMA (B-cell maturation antigen)not yet gradedNo reviewed efficacy summary in this indication
ImeroprubartPhase 3Monoclonal antibodyFcRnnot yet gradedNo reviewed efficacy summary in this indication
PovetaciceptPhase 2Protein / enzyme therapeuticBAFF / APRILnot yet gradedNo reviewed efficacy summary in this indication
Ublituximab (Briumvi)Phase 2Monoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
ABBV-6628
Phase 1/2(overall)
Antibody fragmentComplement C5
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(8 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Soliris (Eculizumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 3NMOSD, Neuromyelitis Optica Spectrum DisordersActive not recruiting
Est. primary completion 2026-12-07 · NCT06724809 · CT.gov ↗
What to watch
Phase 3Neuromyelitis Optica Spectrum Disorders (NMOSD)Recruiting
Est. primary completion 2026-12-31 · NCT07420296 · CT.gov ↗
What to watch
2027 (3)
May 2027 (1)
Phase 3Paroxysmal Nocturnal HemoglobinuriaRecruiting
Est. primary completion 2027-05-28 · NCT06449001 · CT.gov ↗
What to watch
June 2027 (1)
Phase 4Neuromyelitis Optica Spectrum Disorder AttackRecruiting
Est. primary completion 2027-06-30 · NCT07410039 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Paroxysmal Nocturnal HemoglobinuriaNot yet recruiting
Est. primary completion 2027-09 · NCT05731050 · CT.gov ↗
What to watch
2028 (1)
July 2028 (1)
Phase 2Thrombotic MicroangiopathyRecruiting
Est. primary completion 2028-07-10 · NCT07707687 · CT.gov ↗
What to watch
2029 (1)
July 2029 (1)
Phase 2Paroxysmal Nocturnal HemoglobinuriaNot yet recruiting
Est. primary completion 2029-07 · NCT05646563 · CT.gov ↗
What to watch
2030 (1)
January 2030 (1)
Phase 4NMOSDRecruiting
Est. primary completion 2030-01 · NCT07010302 · CT.gov ↗
What to watch

See the full readout calendar ↗